Garni Barkhoudarian
YOU?
Author Swipe
View article: Analysis of Endoscope-Assisted Retrosigmoid Approach versus Modified Transjugular Approach for Microvascular Decompression of the Facial Nerve: A Comparative Cadaveric Study
Analysis of Endoscope-Assisted Retrosigmoid Approach versus Modified Transjugular Approach for Microvascular Decompression of the Facial Nerve: A Comparative Cadaveric Study Open
Despite the greater degree of freedom with MTA, visualizing and manipulating the facial nerve at the root exit zone was comparable between both approaches, with the use of angled endoscopy further improving visualization and accessibility.…
View article: A Survey of 251 Facial Paralysis Patients to Assess Their Educational Preparedness and Symptom Management after Treatment of Vestibular Schwannoma
A Survey of 251 Facial Paralysis Patients to Assess Their Educational Preparedness and Symptom Management after Treatment of Vestibular Schwannoma Open
The aim of this study was to evaluate how patients with vestibular schwannoma (VS) were prepared for facial paralysis (FP). This study comprised an online survey of members of the Acoustic Neuroma Association of America who had FP. A 28-qu…
View article: Pre-radiation Nivolumab plus ipilimumab in patients with newly diagnosed high-grade gliomas
Pre-radiation Nivolumab plus ipilimumab in patients with newly diagnosed high-grade gliomas Open
The limited success of immune checkpoint inhibitors (ICIs) in the adjuvant setting for glioblastoma highlights the need to explore administering ICIs prior to immunosuppressive radiation. To address the feasibility and safety of this appro…
View article: Short-term Surgical Outcomes of Papillary Craniopharyngiomas: A Multicenter Study
Short-term Surgical Outcomes of Papillary Craniopharyngiomas: A Multicenter Study Open
Purpose: Craniopharyngiomas are rare parasellar tumors, and papillary craniopharyngiomas (PCP) represent 8-20% of cases. We assessed surgical outcomes of these very rare tumors among patients treated in the last decade. Methods: Retrospect…
View article: Nasoseptal Flap Enhancement on Early Postoperative MRI Does Not Predict 3-Month Enhancement nor Postoperative Cerebrospinal Fluid Leak Risk
Nasoseptal Flap Enhancement on Early Postoperative MRI Does Not Predict 3-Month Enhancement nor Postoperative Cerebrospinal Fluid Leak Risk Open
BACKGROUND AND OBJECTIVES: The nasoseptal flap (NSF) has been a versatile reconstructive option for extended endonasal skull base surgery, significantly decreasing postoperative cerebrospinal fluid (CSF) leakage rates. One failure mechanis…
View article: Endonasal Surgery High-Risk Carotid Injury Timeout Checklist: Implementation, Institutional Protocol and Experience
Endonasal Surgery High-Risk Carotid Injury Timeout Checklist: Implementation, Institutional Protocol and Experience Open
Objective: Carotid artery injury is a rare, but major complication of endonasal operations. The morbidity and mortality of such a complication can be mitigated by preparedness and a clear plan set in place to address the hemorrhage expedit…
View article: A Reliable Closure Technique for Retromastoid Craniotomy to Avoid Cerebrospinal Fluid Leaks and Meningitis
A Reliable Closure Technique for Retromastoid Craniotomy to Avoid Cerebrospinal Fluid Leaks and Meningitis Open
BACKGROUND AND OBJECTIVES: Postoperative cerebrospinal fluid (CSF) leaks and meningitis are well-known risks of retromastoid craniotomy. Use of abdominal fat grafts, collagen allografts, and rigid or semirigid buttresses have demonstrated …
View article: Immunogenomics and spatial proteomic mapping highlight distinct neuro-immune architectures in melanoma vs. non-melanoma-derived brain metastasis
Immunogenomics and spatial proteomic mapping highlight distinct neuro-immune architectures in melanoma vs. non-melanoma-derived brain metastasis Open
Background Brain metastases (BrMs) are a devastating complication of solid tumours. A better understanding of BrMs biology is needed to address their challenging clinical management. Methods Immunogenomic and digital spatial analyses were …
View article: Supplementary Table S1 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma
Supplementary Table S1 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma Open
Table S1. Individual listing of clinical trial participants.
View article: Supplementary Figure S4 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma
Supplementary Figure S4 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma Open
Supplementary Figure S4. Significant cfmiRs found in plasma and tissues. A. Venn diagram showing the cfmiRs differentially expressed detected in plasma of chordoma patients that were also detected in tissue samples from chordoma patients (…
View article: Supplementary Table S5 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma
Supplementary Table S5 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma Open
Table S5. The top 38 cfmiRs that are commonly DE in chordoma vs normal plasma samples when comparing top 100 most detected, top 100 most significant, and top 100 with highest FC.
View article: Supplementary Table S6 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma
Supplementary Table S6 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma Open
Table S6. Representativeness of Study Participants
View article: Supplementary Table S3 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma
Supplementary Table S3 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma Open
Table S3. Plasma and tissue samples from clinical trial participants used for miR WTA.
View article: Supplementary Figure S2 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma
Supplementary Figure S2 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma Open
Supplementary Figure S2. MRI and CT images of patient P04 with metastatic spinal chordoma in C-spine and lung. C-spine MRI before treatment (A-B) shows C-spine disease (arrows) and 12 months after initiation of high-dose pemetrexed (D-E) s…
View article: Supplementary Table S5 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma
Supplementary Table S5 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma Open
Table S5. The top 38 cfmiRs that are commonly DE in chordoma vs normal plasma samples when comparing top 100 most detected, top 100 most significant, and top 100 with highest FC.
View article: Supplementary Figure S5 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma
Supplementary Figure S5 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma Open
Supplementary Figure S5. Example of top 10 cfmiRs in plasma of clinical trial patients over the course of treatment. A-J: Graphs show changes in individual levels of cfmiRs in patients during course of treatment according to response. No s…
View article: Supplementary Figure S3 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma
Supplementary Figure S3 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma Open
Supplementary Figure S3. CT images of patient P08 treated with innumerable metastatic sacral chordoma to lungs and skin. Chest CT before treatment (A-B) and 6 weeks after initiation of high-dose pemetrexed (D-F) showing shrinkage of some l…
View article: Supplementary Table S4 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma
Supplementary Table S4 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma Open
Table S4. The top 20 cfmiRs that are commonly DE in chordoma vs normal healthy donor plasma samples.
View article: Supplementary Table S1 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma
Supplementary Table S1 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma Open
Table S1. Individual listing of clinical trial participants.
View article: Supplementary Figure S1 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma
Supplementary Figure S1 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma Open
Supplementary Figure S1. MR images of patient P05 with locally advanced clival chordoma. Brain MRI before treatment (A-C) shows left cavernous since disease (arrows), 6 months after initiation of high-dose pemetrexed (D-F), and 12 months a…
View article: Supplementary Table S2 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma
Supplementary Table S2 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma Open
Table S2. Individual listing of additional chordoma tissue samples collected for miR WTA.
View article: Data from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma
Data from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma Open
Purpose:Chordomas are ultrarare tumors of the axial spine and skull-base without approved systemic therapy. Most chordomas have negative expression of thymidylate synthase (TS), suggesting a potential for responding to the antifolate agent…
View article: Supplementary Table S6 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma
Supplementary Table S6 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma Open
Table S6. Representativeness of Study Participants
View article: Supplementary Figure S1 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma
Supplementary Figure S1 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma Open
Supplementary Figure S1. MR images of patient P05 with locally advanced clival chordoma. Brain MRI before treatment (A-C) shows left cavernous since disease (arrows), 6 months after initiation of high-dose pemetrexed (D-F), and 12 months a…
View article: Supplementary Figure S3 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma
Supplementary Figure S3 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma Open
Supplementary Figure S3. CT images of patient P08 treated with innumerable metastatic sacral chordoma to lungs and skin. Chest CT before treatment (A-B) and 6 weeks after initiation of high-dose pemetrexed (D-F) showing shrinkage of some l…
View article: Supplementary Figure S4 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma
Supplementary Figure S4 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma Open
Supplementary Figure S4. Significant cfmiRs found in plasma and tissues. A. Venn diagram showing the cfmiRs differentially expressed detected in plasma of chordoma patients that were also detected in tissue samples from chordoma patients (…
View article: Supplementary Figure S2 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma
Supplementary Figure S2 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma Open
Supplementary Figure S2. MRI and CT images of patient P04 with metastatic spinal chordoma in C-spine and lung. C-spine MRI before treatment (A-B) shows C-spine disease (arrows) and 12 months after initiation of high-dose pemetrexed (D-E) s…
View article: Supplementary Table S3 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma
Supplementary Table S3 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma Open
Table S3. Plasma and tissue samples from clinical trial participants used for miR WTA.
View article: Supplementary Figure S5 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma
Supplementary Figure S5 from Pilot Study of High-Dose Pemetrexed in Patients with Progressive Chordoma Open
Supplementary Figure S5. Example of top 10 cfmiRs in plasma of clinical trial patients over the course of treatment. A-J: Graphs show changes in individual levels of cfmiRs in patients during course of treatment according to response. No s…